Beam Therapeutics (BEAM) Other Non-Current Liabilities (2019 - 2026)
Beam Therapeutics (BEAM) reported Other Non-Current Liabilities of $305000.0 for Q1 2026, down 95.19% year-over-year from $6.3 million in Q1 2025, and up 76.3% on a QoQ basis from $173000.0 in Q4 2025.
Beam Therapeutics (BEAM) has 8 years of Other Non-Current Liabilities data on file, last reported at $305000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 95.19% year-over-year to $305000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $305000.0 (down 95.19% YoY) and the FY2025 annual result came in at $173000.0, down 96.8% from the prior year.
- Other Non-Current Liabilities improved to $305000.0 in Q1 2026 per BEAM's latest filing, from $173000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $30.9 million in Q1 2022 and bottomed at $173000.0 in Q1 2023.
- The 5-year median for Other Non-Current Liabilities is $1.1 million (2024), against an average of $4.0 million.
- Peak annual rise in Other Non-Current Liabilities reached 3371.48% in 2023, while the deepest fall reached 99.44% in 2023.
- Tracing BEAM's Other Non-Current Liabilities over 5 years: stood at $1.4 million in 2022, then jumped by 97.61% to $2.7 million in 2023, then soared by 98.46% to $5.4 million in 2024, then plunged by 96.8% to $173000.0 in 2025, then jumped by 76.3% to $305000.0 in 2026.
- Per Business Quant, the three latest BEAM Other Non-Current Liabilities figures stand at $305000.0 (Q1 2026), $173000.0 (Q4 2025), and $266000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 305,000.00 |
| Dec 31, 2025 | 173,000.00 |
| Sep 30, 2025 | 266,000.00 |
| Jun 30, 2025 | 357,000.00 |
| Mar 31, 2025 | 6.34 Mn |
| Dec 31, 2024 | 5.40 Mn |
| Sep 30, 2024 | 481,000.00 |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 2.86 Mn |
| Dec 31, 2023 | 2.72 Mn |
| Sep 30, 2023 | 4.59 Mn |
| Jun 30, 2023 | 10.59 Mn |
| Mar 31, 2023 | 173,000.00 |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 253,000.00 |
| Jun 30, 2022 | 305,000.00 |
| Mar 31, 2022 | 30.92 Mn |
| Dec 31, 2021 | 2.79 Mn |
| Sep 30, 2021 | 852,000.00 |
| Jun 30, 2021 | 903,000.00 |
| Mar 31, 2021 | 36.82 Mn |
| Dec 31, 2020 | 2.08 Mn |
| Sep 30, 2020 | 2.49 Mn |
| Jun 30, 2020 | 406,000.00 |
| Mar 31, 2020 | 412,000.00 |
| Dec 31, 2019 | 418,000.00 |